MSN Labs gets USFDA nod for generic version of Cangrelor in India

Published On 2021-12-17 07:32 GMT   |   Update On 2023-10-10 10:56 GMT
Advertisement

Hyderabad: Close on the heels of securing Drug Controller General of India's approval for CANREAL injection (generic version of Cangrelor) in India, MSN Laboratories has received tentative approval for the said injection from US Food and Drug Administration (USFDA).

Cangrelor is used in patients undergoing coronary angioplasty to reduce risk of heart attack and blood clots.

MSN Group commented: "Besides reflecting the capability of MSN Laboratories to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US."

Advertisement

It will be manufactured at a FDA and MHRA approved state-of-the-art injectable facility in Hyderabad.

Read also: MSN Labs launches renal cancer treatment Cabolong

Founded in 2003, MSN Group is the research-based pharmaceutical companies based out of Hyderabad, India. The organization presently has 16 state-of-the-art manufacturing facilities (twelve API and four finished dosage facilities) established across India and USA. The Group has an integrated R&D center for both API and formulation under one roof.

Read also: MSN Labs, DRDE ink pact for COVID drug 2-DG

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News